Biomedical Research and Therapy <p><strong>Biomedical Research and Therapy - The Vietnamese Journal of Biomedicine</strong> fully open access journal of original research across a broad spectrum of medical scientific disciplines and sub-specialties. An international peer-reviewed journal, it publishes high quality open access research articles with a special emphasis on basic, translational and clinical research into molecular therapeutics and cellular therapies, including animal models and clinical trials. The peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines.</p> <p>Biomedical Research and Therapy's Editorial Policies follow the recommendations of the <a href="" target="_blank" rel="noopener">International Committee of Medical Journal Editors (ICMJE)</a>, <a href="" target="_blank" rel="noopener">the World Association of Medical Editors (WAME)</a>, and&nbsp;<a href="" target="_blank" rel="noopener">the Committee on Publication Ethics (COPE)</a> for guidance on policies and procedures related to publication ethics.&nbsp;</p> <p>The journal is published monthly, 12 issues per year.</p> <p>&nbsp;</p> <h1 class="sc-gPEVay iUuzmH sc-gacfCG kuiQoX hero_banner_title heading-title">COVID-19 collection</h1> <p><a href="" target="_blank" rel="noopener"><img src="/public/site/images/pvphuc/covid19.jpg" width="184" height="85"></a></p> <div class="sc-dEfkYy cKZZYG hero_banner_text">A collection of new and previously published articles on coronavirus research and treatment. Please click <strong><a href="" target="_blank" rel="noopener">here</a></strong>.</div> <p>&nbsp;</p> BioMedPress (BMP) en-US Biomedical Research and Therapy 2198-4093 <p>Copyright The Author(s) 2017. This article is published with open access by <a href="" target="_blank">BioMedPress</a>. This article is distributed under the terms of the&nbsp;<a href="" target="_blank">Creative Commons Attribution License (CC-BY 4.0)</a> which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.&nbsp;</p> Probiotics: Helpful for the prevention of COVID-19? <p>Up to now, no vaccine has been developed for COVID-19 treatment. Although many scientists are working for the rapid development of a vaccine to control this pandemic, nonetheless, it will take time. If the vaccine will be developed soon, it will not be available to the entire world instantly since the mass production of the vaccine will take time. In this scenario, we will have to take alternative measures to control the COVID-19 pandemic. These alternative approaches include the stimulation of the immune system to fight against viral infections. Among the different approaches to strengthen the immune system, the use of probiotics is the best one. Probiotics can help the body to fight against COVID-19 directly and indirectly. In this review, we comprehensively discuss the use of probiotics for the prevention and control of COVID-19.</p> Nishat Zafar Muhammad Aamir Aslam Ashiq Ali Aisha Khatoon Abdul Nazir Qaisar Tanveer Muhammad Bilal Rabia Kanwar Azka Qadeer Muhammad Sikandar Abdullah Zafar ##submission.copyrightStatement## 2020-11-05 2020-11-05 7 11 4086 4099 10.15419/bmrat.v7i11.646 title description none g Biogenic silver nanoparticles induce apoptosis in Ehrlich ascites carcinoma <p><strong>Introduction</strong>: Plant-mediated synthesis of silver nanoparticles (AgNPs) is accounted as an ecofriendly process. The present study was conducted to estimate the potency of biogenic AgNPs against Ehrlich ascites carcinoma (EAC) cells in vitro and EAC-bearing mice <em>in vivo</em>.</p> <p><strong>Methods</strong>: AgNPs were prepared using mango leaves extract and characterized by X-ray diffraction (XRD), scanning electron microscope (SEM), and transmission electron microscopy (TEM). Ehrlich ascites carcinoma (EAC) mouse model was established by intraperitoneal injection of 1 x 10<sup>6</sup> EAC cells. Biogenic AgNPs- alone or combined with Doxorubicin (DOX)- was administered intraperitoneally day by day for two weeks.</p> <p><strong>Results</strong>: Biologically synthesized AgNPs showed a cytotoxic effect against cultured EAC cells but with less toxicity toward normal cells compared to DOX, which had strong cytotoxicity against both cells. Biogenic AgNPs alone or combined with DOX triggered the cytotoxicity against the EAC-bearing mouse model via decreasing body weight, tumor volume, and the number of viable tumor cells. The combined treatment (AgNPs-DOX) ameliorated the drastic effect induced by injection of EAC cells through improving liver and kidney functions compared to those treated with DOX alone. In addition, the combined treatment showed an elevation in the expression of Bax and caspase-3, and a reduction in the expression of Bcl-2 protein in the EAC cells. Furthermore, this combined treatment effectively arrested the cell cycle at the G<sub>0</sub>/G<sub>1</sub> phase. Moreover, the combined treatment with AgNPs-DOX caused a significant reduction in the activity of ornithine decarboxylase (ODC).</p> <p><strong>Conclusion</strong>: These findings suggest that biogenic AgNPs could be useful in developing a potent combination therapy against different types of cancers.</p> Hamed A. Abosharaf Mohammed Salah Thoria Diab Motonari Tsubaki Tarek M. Mohamed ##submission.copyrightStatement## 2020-11-07 2020-11-07 7 11 4100 4113 10.15419/bmrat.v7i11.647 title description none g